Pliant Therapeutics, Inc.

NASDAQ:PLRX

Biotechnology

Healthcare
$0.81 -3.39%

-$0.04 today

Market cap
$50.14M
Beta
1.21
P/E (TTM)
-0.6
EPS (TTM)
-$1.83
52W Low $1.09High $1.95

Volume 0.15M

Average 0.49M

PLRX Purchases of Investments

Cash used to buy marketable securities and other investments.

Pliant Therapeutics, Inc.NASDAQ: PLRX

Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026

Purchases of investments growth accelerates

Q1 FY2026 purchases of investments of $64.9M (cash outflow) rose 358.7% year over year, ahead of the +46.9% change in trailing-twelve-month purchases of investments. Sequentially, it fell 23.7% from the prior quarter. Over 3 fiscal years it compounded at -14.5% a year.

Context

  • Purchases of investments grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +358.7% holds above the trailing-twelve-month pace of +46.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$64.9M-23.7% QoQ
Last fiscal yearDec 2025
-$203.4M-3.7% YoY
LTMMar 2026
-$254.16M+46.9% YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+358.7%——
1 year-3.7%——
3-year CAGR-14.5%——
5-year CAGR——
10-year CAGR——

Purchases of Investments history

USD · from the cash flow

Latest · FY2025
(203.4M) USD
Year-over-year change
+3.7%

Purchases of Investments vs competitors

How PLRX compares with its peers on the latest reported figures

  • PLRX's LTM Mar 2026 purchases of investments of $254.16M is the largest of the 10 companies compared; the peer median is $91.01M.
  • Its year-over-year change of +46.9% is the 4th highest of 8, against a peer median of +33.1%.
  • Over three fiscal years its annual growth of -14.5% compares with a peer median of +0.8%.
PLRX Competitors Peer median
Purchases of Investments for PLRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PLRXPliant Therapeutics, Inc.LTM Mar 2026$254.16M +46.9%-14.5%—
STROSutro Biopharma, Inc.LTM Mar 2026$247.27M -47.3%+6.9%248.2%
MGNXMacroGenics, Inc.LTM Mar 2026$202.4M +485.0%+20.0%128.9%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$149.91M +9.1%-36.0%—
WHWKWhitehawk Therapeutics IncLTM Dec 2025$148.69M +307.6%+0.8%2081.0%
OVIDOvid Therapeutics Inc.LTM Mar 2026$91.01M +33.1%-19.0%1277.8%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$32.8M -82.6%——
COYACoya Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
CLNNClene Inc.LTM Mar 2026$0 +100.0%—0.0%
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$0 ———
Peer median (excluding PLRX) $91.01M+33.1%+0.8%188.5%

Competitors are the stored peer set for PLRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(97.26M)(123.32M)(161.34M)(210.3M)(149.34M)
Depreciation & Amortization1.54M1.82M1.84M2.13M1.7M
Deferred Income Tax00000
Stock-Based Compensation10.44M22.6M44.48M37.63M26.23M
Change in Working Capital6.92M4.22M1.25M9.09M(15.94M)
Accounts Receivables7.28M15K1.98M00
Inventory00000
Accounts Payables891K(1.35M)2.97M1.43M(5.48M)
Other Working Capital(1.26M)5.55M(3.7M)7.66M(10.46M)
Other Non-Cash Items2.93M52K(2.6M)5.96M9.02M
Operating Cash Flow(75.44M)(94.63M)(116.36M)(155.5M)(128.34M)
Capital Expenditures(1.95M)(1.76M)(921K)(3.85M)(374K)
Acquisitions (Net)(75.65M)148.44M00155K
Purchases of Investments(219.89M)(325.72M)(583.07M)(211.29M)(203.4M)
Sales of Investments295.54M177.27M456.98M355.47M337.91M
Other Investing Activities75.65M(148.44M)000
Investing Cash Flow73.7M(150.2M)(127.01M)140.34M134.29M
Debt Repayment010M019.91M(32.27M)
Common Stock Issued2.98M215.64M275.25M3.21M570K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(457K)1.21M5M00
Financing Cash Flow2.53M226.85M274.41M23.12M(31.7M)
Effect of Forex Changes00000
Net Change in Cash783K(17.98M)31.03M7.95M(25.74M)
Free Cash Flow(77.4M)(96.39M)(117.28M)(159.35M)(128.71M)

Pliant Therapeutics, Inc.

NASDAQ:PLRX

Intrinsic Alpha fair value

Locked

Current Price

$0.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.